Actinium Pharmaceuticals, Inc. is a New York, New York based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 isotopes in association with monoclonal antibodies. The Company also develops other radiopharmaceuticals for select applications.
For more information:
Visit our web site www.actiniumpharmaceuticals.com or contact:
Jack Talley, CEO Actinium Pharmaceuticals Inc. Tel: (646) 459-4201 E-mail: firstname.lastname@example.orgInvestors: Jeff Ramson ProActive Capital Group, LLC Tel: (646) 863-6341 E-mail: email@example.com www.proactivecrg.com Media: Dennis S. Dobson Jr., 203-258-0159 Forward-Looking Statement for Actinium Pharmaceuticals, Inc. This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. SOURCE Actinium Pharmaceuticals, Inc.